SAB BIOTHERAPEUTICS, INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
SAB BIOTHERAPEUTICS, INC. (SABS) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $92.80 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-06
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $92.80M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $97.40M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $38.00M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $11.80M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $92.80M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $97.40M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $38.00M 10-K · filed 2026-03-09 |
| 2025-09-30 | $11.80M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $5.20M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $5.70M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $6.30M 10-K · filed 2025-03-31 |
| 2024-09-30 | $6.90M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $5.20M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $6.80M 10-Q · filed 2024-05-20 |
| 2023-12-31 | $3.10M 10-K · filed 2024-03-29 |
| 2023-09-30 | $3.60M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $4.20M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $4.50M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $4.20M 10-K · filed 2023-04-14 |
| 2022-09-30 | $5.10M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $5.20M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $7.50M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $6.60M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |